A Single-Arm Phase II Trial of Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy
Latest Information Update: 05 Jun 2023
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Jun 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified27 Jun 2021).
- 27 Jun 2021 Status changed from not yet recruiting to recruiting.
- 23 Dec 2020 New trial record